Systemic inflammatory mediators in post-traumatic complex regional pain syndrome (CRPS I) - longitudinal investigations and differences to control groups.
about
Elevated Plasma Levels of sIL-2R in Complex Regional Pain Syndrome: A Pathogenic Role for T-Lymphocytes?Estrogen receptors involvement in intervertebral discogenic pain of the elderly women: colocalization and correlation with the expression of Substance P in nucleus pulposus.Mast cells: versatile gatekeepers of pain.Morphological macrovascular alterations in complex regional pain syndrome type I demonstrated by increased intima-media thickness.Neuropeptides contribute to peripheral nociceptive sensitization by regulating interleukin-1β production in keratinocytesPreventive Treatment with Ketamine Attenuates the Ischaemia-Reperfusion Response in a Chronic Postischaemia Pain ModelInflammation in complex regional pain syndrome: a systematic review and meta-analysisInflaming the brain: CRPS a model disease to understand neuroimmune interactions in chronic pain.Oxidative stress in Complex Regional Pain Syndrome (CRPS): no systemically elevated levels of malondialdehyde, F2-isoprostanes and 8OHdG in a selected sample of patients.Calcitonin gene-related peptide and pain: a systematic review.Mast cells: a new target in the treatment of complex regional pain syndrome?Management of patients with complex regional pain syndrome type I.Complex regional pain syndrome: state of the art update.Targeting oxidative injury and cytokines' activity in the treatment with anti-tumor necrosis factor-α antibody for complex regional pain syndrome 1.A Novel Compound Analgesic Cream (Ketamine, Pentoxifylline, Clonidine, DMSO) for Complex Regional Pain Syndrome Patients.The Rodent Tibia Fracture Model: A Critical Review and Comparison with the Complex Regional Pain Syndrome Literature.Predictors of Responsiveness to Bisphosphonate Treatment in Patients with Complex Regional Pain Syndrome Type I: A Retrospective Chart Analysis.Platelet and Erythrocyte Indexes in Complex Regional Pain Syndrome Type I
P2860
Q33786864-E558A5C2-066C-4DC4-9FD2-0B419273F130Q33888709-A5692DCE-2FA4-4EDD-AA3C-A5CE1DA87BDAQ34225889-66F1CC99-5721-4EAE-84E6-0394675C12AEQ34577386-650711D8-1D19-4FA2-A4E0-E9A307AB890EQ35068859-00D3C9B1-F7B6-4B49-9BAD-DB6C29B5A8CAQ35806439-4F04E7C1-9555-4097-8BED-2951DD3D1E02Q36659427-89F7A2B4-EE78-4416-B96F-544C3D523F62Q36681040-021C2CF0-AD96-4123-800C-65A695CC9A26Q36820521-8BC85DD1-3F4B-4E95-8A9D-931265284612Q37707191-1C43B7F0-F1EF-4854-A97D-940AF6CCCCE8Q38089303-4AE1C59B-CEB1-4DE1-A91D-32CF251E3114Q38755588-545A7986-470E-4335-8587-2196E5228064Q42907041-C4C90B59-E20C-4264-AA10-3123F06B32BAQ44902683-A030ADB4-92FD-4D3A-8C46-5B78623ACCE5Q47630066-CC9AEA84-F713-41FF-A510-3D8847C17150Q52312548-70FAEB01-B6C1-4E3D-828F-302A81F10344Q52914656-1D317A0C-2E56-42E7-8EA6-37615FB6F0CEQ58134815-7439943F-63D9-40BC-8102-6EA4E438A855
P2860
Systemic inflammatory mediators in post-traumatic complex regional pain syndrome (CRPS I) - longitudinal investigations and differences to control groups.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Systemic inflammatory mediator ...... differences to control groups.
@ast
Systemic inflammatory mediator ...... differences to control groups.
@en
type
label
Systemic inflammatory mediator ...... differences to control groups.
@ast
Systemic inflammatory mediator ...... differences to control groups.
@en
prefLabel
Systemic inflammatory mediator ...... differences to control groups.
@ast
Systemic inflammatory mediator ...... differences to control groups.
@en
P2093
P2860
P1476
Systemic inflammatory mediator ...... differences to control groups.
@en
P2093
A Scherens
Christian Schinkel
G Roellecke
P2860
P2888
P304
P356
10.1186/2047-783X-14-3-130
P407
P577
2009-03-01T00:00:00Z
P6179
1047518098